(Q33346607)

26 July 2017

title

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. (English)

1 reference

chronic lymphocytic leukemia

26 July 2017

0 references

1 reference

1 reference

5

Vardiman JW

1 reference

26 July 2017

6

Larson RA

1 reference

26 July 2017

Byrd JC

1

1 reference

26 July 2017

Peterson B

2

1 reference

26 July 2017

Piro L

3

1 reference

26 July 2017

Saven A

4

1 reference

26 July 2017

Schiffer C

7

1 reference

26 July 2017

language of work or name

1 reference

1 February 2003

1 reference

26 July 2017

1 reference

26 July 2017

volume

17

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

323-327

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402752

26 July 2017

exact match

0 references

cites work

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Infectious and immunosuppressive complications of purine analog therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

7 January 2021

Low-dose deoxycoformycin in lymphoid malignancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

7 January 2021

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

7 January 2021

2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

7 January 2021

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

7 January 2021

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402752

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402752

1 reference

Dimensions Publication ID

26 July 2017

1024080572

0 references

1 reference